A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Dravet Syndrome
Sponsor: Longboard Pharmaceuticals
A observational or N/A phase clinical study on Dravet Syndrome, this trial is actively recruiting participants. The trial is conducted by Longboard Pharmaceuticals and has accumulated 15 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
▶ Show 10 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Feb 2025 [monthly]
Recruiting PHASE3
First recorded
Sep 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Contact Information
- Longboard Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerp, Belgium , Atlanta, United States , Aurora, United States , Austin, United States , Barcelona, Spain , Barcelona, Spain , Beijing, China , Beijing, China , Belgrade, Serbia , Belgrade, Serbia and 87 more locations